See the DrugPatentWatch profile for Calquence

Calquence Drug News

What is Calquence and what is it used for?

Calquence, known generically as acalabrutinib, is a medication used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [1]. It is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor [1][2].

How does Calquence work?

Calquence works by blocking the action of a protein called Bruton's tyrosine kinase (BTK) [1][2]. BTK is important for the growth and survival of certain white blood cells, including B cells, which are involved in the development of MCL and CLL [1][2]. By inhibiting BTK, Calquence helps to reduce the number of cancer cells [1].

What are the latest developments and news regarding Calquence?

Recent news concerning Calquence often revolves around its clinical trial data, regulatory approvals, and its positioning within the competitive landscape of BTK inhibitors [3][4]. For instance, studies continue to evaluate its efficacy and safety in various patient populations and treatment settings for MCL and CLL [3]. Updates may also include new indications or combinations with other therapies being explored in clinical trials [4].

When does the patent for Calquence expire?

The patent expiry dates for Calquence are a significant point of interest for the pharmaceutical industry, as they signal potential market entry for generic versions. According to DrugPatentWatch.com, the patent landscape for acalabrutinib is complex and involves multiple patents covering the compound, its manufacturing, and its uses. Specific patent expiry dates can vary and are subject to legal challenges and extensions [5]. For precise details, consulting a specialized patent tracking service like DrugPatentWatch.com is recommended.

Who manufactures Calquence?

Calquence is manufactured by AstraZeneca [1].

How does Calquence compare to other BTK inhibitors?

Calqueng competes in a class of drugs known as BTK inhibitors. Other prominent drugs in this class include ibrutinib (Imbruvica) and zanubrutinib (Brukinsa) [6]. These drugs share a similar mechanism of action but differ in their selectivity for BTK and their side effect profiles [6][7]. Clinical trials often compare Calquence directly or indirectly against these other agents, assessing factors like efficacy, tolerability, and patient outcomes [7].

What are the potential side effects of Calquence?

Common side effects reported with Calquence include diarrhea, fatigue, headache, muscle pain, and bruising [1]. More serious side effects can occur, such as infections, bleeding events, heart rhythm problems (like atrial fibrillation), and decreased blood cell counts [1]. Patients should discuss any potential side effects with their healthcare provider.

What is the clinical data supporting Calquence?

Calquence's approval is based on robust clinical trial data demonstrating its effectiveness in treating MCL and CLL [3][4]. Key studies have shown significant response rates and progression-free survival benefits in patients with these conditions, often in comparison to standard therapies or placebo [3][4]. Ongoing research continues to gather data on long-term outcomes and its use in different treatment scenarios.

Are there any risks associated with Calquence treatment?

Beyond the side effects, risks associated with Calquence treatment include the potential for serious infections due to its impact on the immune system [1]. Bleeding risks are also a concern, particularly in combination with other medications that affect blood clotting [1]. Additionally, cardiovascular events and the development of secondary cancers have been monitored in patients treated with BTK inhibitors [1].

What are the regulatory approvals for Calquence?

Calquence has received regulatory approval from major health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of specific indications of MCL and CLL [1][8]. These approvals are based on the comprehensive clinical trial data submitted by the manufacturer.

---
Cited Sources:

[1] https://www.calquence.com/
[2] https://www.drugbank.ca/drugs/DB11588
[3] https://www.astrazeneca.com/
[4] https://news.cancerresearchuk.org/
[5] https://drugpatentwatch.com/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2103023
[7] https://ascopubs.org/doi/full/10.1200/JCO.2018.79.3640
[8] https://www.ema.europa.eu/en